A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico.
Juan Carlos Garnica CuéllarEnrique Morales-VillegasCarmen Alicia López-ForeroBárbara Monroy-CruzBhrugu ParitiSwati DeshwalManisha SekharanMariana Osorio-HernándezIda Caterina García-AppendiniPublished in: PharmacoEconomics - open (2023)
When integrating the greater clinical efficacy of IDegLira with its annual cost, it can be shown that within 1 year, IDegLira is the best option in terms of value for money for payers in a private healthcare setting in Mexico in comparison with other forms of basal insulin intensification. Thus, investing in IDegLira not only represents a greater clinical benefit, but also an economical one for payers.